Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Japan Tobacco obtains rights to Terumo antiplatelet agent

Oct. 30, 1998

Ajinomoto prepares extensive series with anticoagulant efficacy

Oct. 30, 1998

Ibex to resume testing of heparin-reversing agent

Oct. 30, 1998

Melagatran in different vehicles compared in rat model of thrombosis

Oct. 28, 1998

Advisory committee decides against recommending approval for new anticoagulant

Oct. 27, 1998

RPR presents clinical findings with gpIIb/IIIa antagonist; product dropped due to dosing problems

Oct. 27, 1998

In vitro studies point to potent, long-lasting antiplatelet effects for XV-459/DMP-754

Oct. 26, 1998

Platelet collagen receptors targeted for development of new antiplatelet therapies

Oct. 23, 1998

Effects of DX-9065a on platelet activation reported at international congress

Oct. 23, 1998

SR-121787: the most potent fibrinogen antagonist reported to date

Oct. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.